Literature DB >> 20207095

Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods.

Michael A Pfaller1, Linda Boyken, Richard J Hollis, Jennifer Kroeger, Shawn A Messer, Shailesh Tendolkar, Daniel J Diekema.   

Abstract

Antifungal susceptibility testing of Aspergillus spp. against caspofungin has been standardized by the Clinical and Laboratory Standards Institute (CLSI). Recent studies have documented breakthrough infections with Aspergillus spp. for which the minimum effective concentration (MEC) for caspofungin ranged from 0.25 to 8 microg/mL. We tested a collection of 1590 clinical isolates of Aspergillus spp. (188 Aspergillus flavus, 1187 Aspergillus fumigatus, 114 Aspergillus niger, 71 Aspergillus terreus, and 30 Aspergillus versicolor) against caspofungin using the CLSI broth microdilution method. An epidemiologic cutoff value (ECV) of <or=0.06 microg/mL encompassed the wild-type (WT) MEC distribution (percentage of MECs) of A. flavus (99.5%), A. fumigatus (98.7%), A. niger (100%), and A. terreus (97.2%), and an ECV of <or=0.12 microg/mL encompassed the WT distribution of A. versicolor (96.7%). A total of 20 strains showed MECs that were outside the ECVs: 1 A. flavus (0.12 microg/mL), 16 A. fumigatus (0.12 microg/mL [13], 1 microg/mL [1], 2 microg/mL [2]), 2 A. terreus (0.12 [1] and >8 microg/mL [1]), and 1 A. versicolor (4 microg/mL). The establishment of the WT MEC distributions and ECVs for caspofungin and the major species of Aspergillus will be useful in resistance surveillance and is an important step toward the development of clinical breakpoints. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20207095     DOI: 10.1016/j.diagmicrobio.2010.01.001

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  15 in total

1.  Aspergillus terreus infection in a sutureless self-sealing incision made during cataract surgery.

Authors:  Elif Erdem; Hazal Kandemir; Sevtap Arıkan-Akdağlı; Ebru Esen; Arbil Açıkalın; Meltem Yağmur; Macit İlkit
Journal:  Mycopathologia       Date:  2014-11-02       Impact factor: 2.574

2.  Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species.

Authors:  Elena De Carolis; Antonietta Vella; Ada R Florio; Patrizia Posteraro; David S Perlin; Maurizio Sanguinetti; Brunella Posteraro
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

Review 3.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.

Authors:  Shawn R Lockhart; Alicia J Zimbeck; John W Baddley; Kieren A Marr; David R Andes; Thomas J Walsh; Carol A Kauffman; Dimitrios P Kontoyiannis; James I Ito; Peter G Pappas; Tom Chiller
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

5.  Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.

Authors:  J A Olson; J Schwartz; D Hahka; A George; R T Proffitt; J P Adler-Moore
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

6.  Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

Authors:  A Espinel-Ingroff; A Fothergill; J Fuller; E Johnson; T Pelaez; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

7.  Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan.

Authors:  Masato Tashiro; Koichi Izumikawa; Asuka Minematsu; Katsuji Hirano; Naoki Iwanaga; Shotaro Ide; Tomo Mihara; Naoki Hosogaya; Takahiro Takazono; Yoshitomo Morinaga; Shigeki Nakamura; Shintaro Kurihara; Yoshifumi Imamura; Taiga Miyazaki; Tomoya Nishino; Misuzu Tsukamoto; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Akira Yasuoka; Takayoshi Tashiro; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

Review 8.  Current perspectives on echinocandin class drugs.

Authors:  David S Perlin
Journal:  Future Microbiol       Date:  2011-04       Impact factor: 3.165

9.  Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.

Authors:  Shawn R Lockhart; Elizabeth L Berkow
Journal:  Clin Microbiol Newsl       Date:  2016-07

10.  Susceptibility screening of hyphae-forming fungi with a new, easy, and fast inoculum preparation method.

Authors:  Arno Schmalreck; Birgit Willinger; Viktor Czaika; Wolfgang Fegeler; Karsten Becker; Gerhard Blum; Cornelia Lass-Flörl
Journal:  Mycopathologia       Date:  2012-08-04       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.